Business
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
-- Reduction in Mortality Risk with Narsoplimab -- SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab
About this update from Omeros Corporation
[{"type":"text","content":"\n-- Reduction in Mortality Risk with Narsoplimab --\n\n SEATTLE--(BUSINESS WIRE)--\nOmeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Analysis in the randomized patient population shows that the addition of narsoplimab to treatment of critically ill patients with COVID-19 reduces the mortality risk (hazard ratio [HR]=0.81, with probability [HR","length":641,"tagName":"div"}]